TrialNeuro-oncology2021

A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study.

Jason Fangusaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.